Medical Pharmacology: Chapter 7: Hypertension — Clinical and Pharmacological Series -- Module: HTN-02 — Diagnosis, Evaluation, and Secondary Causes

Chapter 7: Hypertension — Clinical and Pharmacological Series — Module: HTN-02 — Diagnosis, Evaluation, and Secondary Causes
Tier: Tier 3

1. A 58-year-old woman with hypertension and CKD stage 4 (eGFR 22 mL/min/1.73m²) was taken off her ACE inhibitor 4 months ago due to hyperkalemia (K+ 6.0 mEq/L). She is now on amlodipine only and her urine ACR has risen from 380 to 740 mg/g. Her nephrologist wants to restart RAAS blockade. Her potassium is currently 5.6 mEq/L on amlodipine alone. Which of the following most accurately describes the approach that would allow safe RAAS reintroduction?

A) RAAS blockade is permanently contraindicated once hyperkalemia has occurred in CKD stage 4; amlodipine should be maximized and a diuretic added instead
B) The ACE inhibitor can be restarted at full dose immediately because the current potassium of 5.6 mEq/L on amlodipine alone confirms sufficient renal reserve for potassium excretion
C) A potassium binder such as patiromer or sodium zirconium cyclosilicate (SZC) can be initiated to lower serum potassium to a safer baseline before reintroducing RAAS blockade at low dose with close monitoring — the worsening proteinuria from loss of efferent arteriole vasodilation confirms that RAAS blockade is pharmacologically necessary for renal protection, and potassium binders exist specifically to enable this therapy in CKD patients with hyperkalemia
D) Dual RAAS blockade with both an ACE inhibitor and an ARB should be initiated to achieve maximal intraglomerular pressure reduction before the potassium can rise further
E) The worsening proteinuria is explained entirely by natural CKD progression and is unrelated to stopping the ACE inhibitor; no pharmacological intervention is indicated beyond continuing amlodipine

ANSWER: C

Rationale:

Option C is correct: the worsening proteinuria following ACE inhibitor discontinuation is pharmacologically explained — loss of efferent arteriole vasodilation has allowed intraglomerular pressure to rise, worsening the protein leak; patiromer and SZC are potassium binders specifically indicated to enable continued or reinstated RAAS inhibitor therapy in CKD patients with hyperkalemia, lowering baseline potassium to allow safe reintroduction at low dose with close monitoring.

Option A: Option A is incorrect — hyperkalemia in CKD is not a permanent contraindication to RAAS blockade; it is a manageable barrier addressable with potassium binders and dietary modification.
Option B: Option B is incorrect — restarting at full dose with a baseline potassium of 5.6 mEq/L in CKD stage 4 creates high risk of recurrent dangerous hyperkalemia; careful dose titration after potassium lowering is required.
Option D: Option D is incorrect — dual RAAS blockade is specifically not recommended (ONTARGET trial — a dual RAAS blockade trial showing increased AKI and hyperkalemia without cardiovascular benefit); the goal is to safely reintroduce single-agent RAAS blockade.
Option E: Option E is incorrect — the temporal correlation between ACE inhibitor discontinuation and proteinuria worsening is pharmacologically explained; dismissing it as natural progression ignores the reversible mechanism.

2. A 39-year-old woman with hypertension develops a persistent dry cough 4 weeks after starting ramipril. Her physician switches her to losartan. Eight months later her BP is again uncontrolled and her cardiologist recommends sacubitril-valsartan given her newly diagnosed HFrEF (heart failure with reduced ejection fraction, EF 35%). She has no history of angioedema. Which of the following most accurately describes the pharmacological considerations for transitioning from losartan to sacubitril-valsartan in this patient?

A) Sacubitril-valsartan can be started immediately after the last dose of losartan because both contain an ARB component and there is no washout period required between agents in the same class
B) A 36-hour washout period after stopping losartan is required before starting sacubitril-valsartan — sacubitril inhibits neprilysin, which degrades vasoactive peptides including bradykinin; combining sacubitril with an ACE inhibitor would cause dangerous bradykinin accumulation and angioedema, necessitating a 36-hour washout from ACE inhibitors before starting; switching from an ARB to sacubitril-valsartan does not require a washout because ARBs do not affect bradykinin metabolism
C) Sacubitril-valsartan is contraindicated in any patient who has ever taken an ACE inhibitor regardless of how long ago, because residual ACE inhibitor receptor binding persists indefinitely and sacubitril-induced bradykinin accumulation will cause angioedema
D) The dry cough from ramipril confirms she has a bradykinin sensitivity that makes sacubitril-valsartan dangerous — neprilysin inhibition will cause the same bradykinin accumulation as the ACE inhibitor, producing recurrent cough and high angioedema risk; a different drug class should be chosen
E) Sacubitril-valsartan cannot be used in HFrEF because neprilysin inhibition raises BNP (B-type natriuretic peptide) levels, making cardiac biomarker monitoring unreliable during heart failure management

ANSWER: B

Rationale:

Option B is correct: the 36-hour washout is required when switching from an ACE inhibitor to sacubitril-valsartan (not from an ARB); ACE inhibitors prevent bradykinin degradation, and sacubitril additionally inhibits neprilysin (another bradykinin-degrading enzyme) — together they cause dangerous bradykinin excess and angioedema; since this patient is on an ARB (losartan), which does not affect bradykinin metabolism, no washout is required and the switch can be made directly.

Option A: Option A is incorrect — while no washout is needed from an ARB, the transition is not instantaneous; the clinical guidance is to substitute sacubitril-valsartan for the ARB, which this patient can do directly since she is on losartan.
Option C: Option C is incorrect — there is no indefinite contraindication after prior ACE inhibitor use; the 36-hour washout from an ACE inhibitor is the safety requirement, not a permanent exclusion.
Option D: Option D is incorrect — ACE inhibitor cough is a bradykinin-mediated class effect of ACE inhibitors; ARBs and sacubitril-valsartan do not cause cough through the same mechanism; sacubitril-valsartan does raise bradykinin to some degree through neprilysin inhibition but this does not reproduce the cough mechanism of ACE inhibition in the same way.
Option E: Option E is incorrect — sacubitril-valsartan is specifically approved for HFrEF and is the basis of PARADIGM-HF (a trial of sacubitril-valsartan vs enalapril in HFrEF demonstrating superior cardiovascular outcomes); rising BNP with neprilysin inhibition is a known monitoring consideration but is not a contraindication.

3. A 51-year-old man with treatment-resistant hypertension (BP 172/106 mmHg on lisinopril 40 mg, amlodipine 10 mg, and chlorthalidone 25 mg with confirmed adherence) undergoes secondary cause workup. Aldosterone-to-renin ratio (ARR) is 38 with plasma aldosterone 19 ng/dL and plasma renin activity 0.5 ng/mL/hr. He is currently on the three antihypertensives listed. His potassium is 3.4 mEq/L. Which of the following most accurately addresses the interpretation of this ARR in the context of his medication list?

A) An ARR of 38 is diagnostic of primary aldosteronism regardless of concurrent medications; confirmatory testing can be skipped and spironolactone should be started immediately
B) The ACE inhibitor (lisinopril) is causing a false-positive ARR by directly suppressing renin through feedback inhibition, making the result uninterpretable; lisinopril must be stopped for 4 weeks before the test can be repeated
C) Chlorthalidone stimulates renin secretion through volume depletion, which would tend to lower the ARR and potentially produce a false-negative result — the fact that the ARR is still elevated at 38 despite this renin-stimulating effect of chlorthalidone makes the result more convincing, not less; the hypokalemia of 3.4 mEq/L is an additional biochemical clue for primary aldosteronism; confirmatory testing should proceed
D) Lisinopril raises the ARR by suppressing aldosterone, making a true ARR of 38 impossible in a patient on an ACE inhibitor; the result should be dismissed as artifactual
E) The ARR of 38 is below the threshold of 40 required for a positive screening result; the test is negative and no further evaluation for primary aldosteronism is warranted

ANSWER: C

Rationale:

Option C is correct: chlorthalidone stimulates renin secretion through volume depletion, which would lower the ARR (by raising the denominator); the fact that the ARR remains elevated at 38 despite this renin-stimulating drug makes the result more convincing for autonomous aldosterone secretion, not less; additionally, spontaneous hypokalemia of 3.4 mEq/L in a patient not on a potassium-wasting diuretic is a strong additional clue for primary aldosteronism; confirmatory testing should proceed.

Option A: Option A is incorrect — ARR alone is a screening result, not diagnostic; confirmatory testing is required.
Option B: Option B is incorrect — ACE inhibitors affect renin through volume and pressure changes but tend to raise renin (by reducing Ang II feedback suppression), which would lower the ARR and produce a false-negative; they do not directly suppress renin and do not produce false-positive ARR.
Option D: Option D is incorrect — lisinopril reduces Ang II which tends to raise renin (stimulating renin release through reduced feedback inhibition), lowering the ARR denominator effect in the opposite direction described; the premise is pharmacologically wrong.
Option E: Option E is incorrect — the threshold for a suspicious ARR is approximately 20–30, not 40; an ARR of 38 is above standard suspicious thresholds.

4. A 67-year-old man with hypertension, HFrEF (heart failure with reduced ejection fraction, EF 30%), and newly diagnosed hypertension has BP 154/92 mmHg on amlodipine 10 mg. His cardiologist initiates carvedilol for HFrEF. Three months later BP is 142/88 mmHg. The cardiologist wants to add diltiazem for additional rate control in newly discovered atrial fibrillation. Which of the following most accurately identifies the pharmacological danger of this addition?

A) Diltiazem has no significant interaction with carvedilol; the concern is solely about diltiazem's interaction with amlodipine through additive calcium channel blockade causing peripheral edema
B) Diltiazem is preferred over verapamil in HFrEF because diltiazem has no negative inotropic effect at therapeutic doses, making it the only safe non-dihydropyridine CCB in systolic dysfunction
C) Diltiazem is acceptable in this patient because its rate-controlling effect in AF offsets carvedilol's heart rate reduction, producing a balanced net chronotropic effect that is safe in HFrEF
D) The primary concern with diltiazem in this patient is its inhibition of CYP3A4, which raises carvedilol plasma levels and increases the risk of carvedilol-induced bronchospasm in elderly patients
E) Diltiazem should be avoided in HFrEF with reduced EF because non-dihydropyridine CCBs (calcium channel blockers) have significant negative inotropic and chronotropic effects; combined with carvedilol's negative inotropic and chronotropic effects from beta-blockade, this combination can precipitate acute hemodynamic decompensation in a patient with already-impaired systolic function

ANSWER: E

Rationale:

Option E is correct: non-dihydropyridine CCBs — diltiazem and verapamil — have significant negative inotropic effects that reduce myocardial contractility; in a patient with HFrEF and EF of 30%, adding diltiazem on top of carvedilol's beta-blockade (which already reduces heart rate and cardiac output) can precipitate acute hemodynamic decompensation; non-dihydropyridine CCBs are specifically contraindicated in HFrEF with reduced EF; alternative rate control options in AF with HFrEF include digoxin or amiodarone.

Option A: Option A is incorrect — diltiazem has clinically significant pharmacodynamic interactions in HFrEF beyond peripheral edema; the danger is hemodynamic, not additive peripheral edema.
Option C: Option C is incorrect — the net effect of diltiazem plus carvedilol is additive negative inotropy and chronotropy in a patient with severely reduced systolic function; this is not a balanced or safe combination.
Option D: Option D is incorrect — while diltiazem does inhibit CYP3A4 and can raise carvedilol levels, the primary concern here is negative inotropic additive effect in HFrEF, not bronchospasm risk.
Option B: Option B is incorrect — both diltiazem and verapamil have significant negative inotropic effects in HFrEF; neither is safe in systolic dysfunction at standard doses; this distinction is pharmacologically incorrect.

5. A 44-year-old woman with hypertension and bilateral adrenal incidentalomas (both less than 2 cm, lipid-rich on CT, non-enhancing) has a normal ARR, normal plasma metanephrines, and a normal 1 mg overnight dexamethasone suppression test. Her BP is 158/96 mmHg. Which of the following most accurately describes the relationship between her bilateral adrenal incidentalomas and her hypertension, and the appropriate pharmacological approach?

A) Bilateral non-functioning adrenal incidentalomas confirmed by normal biochemical workup are incidental findings not causally responsible for her hypertension; she should be treated as having primary hypertension with standard first-line antihypertensive therapy, with ongoing imaging surveillance of the incidentalomas per endocrinology guidelines
B) Bilateral adrenal incidentalomas always indicate bilateral adrenal hyperplasia causing subclinical primary aldosteronism; spironolactone should be initiated empirically even with a normal ARR
C) Bilateral adrenal incidentalomas in a hypertensive patient always require adrenalectomy before pharmacological therapy is initiated, as leaving adrenal tissue in place undermines antihypertensive drug efficacy
D) The normal dexamethasone suppression test excludes all forms of Cushing syndrome including mild autonomous cortisol secretion; no additional endocrine testing is warranted and the incidentalomas can be ignored
E) Bilateral lipid-rich non-enhancing adrenal incidentalomas under 2 cm are highly suspicious for bilateral adrenocortical carcinoma; oncological referral should precede antihypertensive therapy

ANSWER: A

Rationale:

Option A is correct: adrenal incidentalomas confirmed as non-functioning by normal ARR (excluding primary aldosteronism), normal plasma metanephrines (excluding pheochromocytoma), and normal dexamethasone suppression test (excluding overt Cushing syndrome) are not causally responsible for hypertension; standard primary hypertension management with antihypertensive therapy proceeds normally, with interval imaging surveillance of the incidentalomas.

Option B: Option B is incorrect — bilateral incidentalomas with normal ARR are not empirically treated with spironolactone; biochemical confirmation of aldosterone excess is required.
Option C: Option C is incorrect — non-functioning incidentalomas do not require adrenalectomy before antihypertensive therapy.
Option D: Option D is incorrect — while the 1 mg DST is the standard first-line screening test, some guidelines recommend additional testing (24-hour urinary free cortisol or late-night salivary cortisol) for mild autonomous cortisol secretion in adrenal incidentaloma patients; a single normal DST does not mean the incidentalomas can be "ignored" — interval imaging surveillance remains necessary.
Option E: Option E is incorrect — bilateral lipid-rich non-enhancing adrenal incidentalomas under 2 cm have very low probability of malignancy; the imaging characteristics are reassuring and oncological referral is not indicated based on these features alone.

6. A 33-year-old woman with hypertension is being considered for antihypertensive therapy. She is planning a pregnancy within the next 12 months and is currently using barrier contraception. Her BP is 152/94 mmHg. She asks which antihypertensives are safe to use now and which she must stop before conception. Which of the following most accurately addresses this question?

A) All antihypertensives should be stopped before conception because any pharmacological BP lowering during pregnancy carries unacceptable fetal risk; hypertension in pregnancy is managed with dietary sodium restriction alone
B) ACE inhibitors and ARBs must be stopped before conception or immediately upon confirmed pregnancy — both classes cause fetal renal tubular dysplasia, oligohydramnios, and skull ossification defects through blockade of the fetal RAAS during critical renal development; acceptable alternatives while trying to conceive include methyldopa, labetalol, or nifedipine extended-release, which have established safety records in pregnancy
C) ACE inhibitors are safe during the first trimester and only need to be stopped after 12 weeks; ARBs are safe throughout pregnancy and can be continued without interruption
D) Only beta-blockers are contraindicated before conception because propranolol causes uterine contractility inhibition that prevents implantation; all other antihypertensive classes including ACE inhibitors and ARBs are safe to continue through conception and the first trimester
E) All antihypertensives are safe throughout pregnancy; the concern about fetal harm from antihypertensives applies only to very high doses that exceed standard therapeutic ranges

ANSWER: B

Rationale:

Option B is correct: ACE inhibitors and ARBs are contraindicated in pregnancy — they cause fetal RAAS blockade during critical renal developmental periods (second and third trimesters primarily), producing fetal renal tubular dysplasia, oligohydramnios (from fetal anuria), pulmonary hypoplasia, and skull ossification defects; women planning pregnancy should switch to acceptable alternatives (methyldopa, labetalol, or nifedipine extended-release) before conception so that no RAAS inhibitor exposure occurs during early pregnancy.

Option A: Option A is incorrect — hypertension in pregnancy does require pharmacological treatment when BP is elevated to avoid maternal stroke and other cardiovascular complications; sodium restriction alone is insufficient.
Option C: Option C is incorrect — ACE inhibitors are not safe in the first trimester; the fetal RAAS is active from early gestation and RAAS inhibitor exposure should be avoided throughout pregnancy; the old guidance suggesting first-trimester safety has been revised.
Option D: Option D is incorrect — beta-blockers do not inhibit uterine implantation; metoprolol and labetalol are commonly used in pregnancy; the agents specifically contraindicated are ACE inhibitors and ARBs.
Option E: Option E is incorrect — the fetal harm from ACE inhibitors and ARBs occurs at standard therapeutic doses through the pharmacological mechanism of RAAS blockade in the fetus, not only at supratherapeutic doses.

7. A 61-year-old man with hypertension, type 2 diabetes, and CKD stage 3b is on maximum-dose lisinopril and amlodipine. His BP is 148/88 mmHg. His physician wants to add a diuretic. His eGFR is 34 mL/min/1.73m² and he has 3+ pitting edema. Which of the following most accurately guides diuretic selection in this patient?

A) Hydrochlorothiazide 25 mg daily is the preferred diuretic because thiazides are first-line for all hypertensive patients regardless of renal function and their volume-reducing effect is superior to loop diuretics in CKD
B) Spironolactone is the preferred diuretic because mineralocorticoid receptor antagonism provides specific renoprotective benefit in CKD with diabetes beyond volume reduction
C) No diuretic should be added in CKD stage 3b because any further reduction in intravascular volume will precipitate AKI through reduced renal perfusion pressure
D) A loop diuretic such as furosemide is the preferred agent because thiazide diuretics lose meaningful natriuretic efficacy at eGFR below approximately 30 mL/min/1.73m² — while this patient's eGFR of 34 is at the margin, the significant edema and volume overload suggest impaired natriuretic capacity better addressed by a loop diuretic, which acts on the thick ascending limb and retains efficacy throughout the CKD spectrum
E) Amiloride is the preferred diuretic in CKD with diabetes because ENaC (epithelial sodium channel) blockade provides potassium-sparing volume reduction without the hyperkalemia risk of other potassium-sparing agents in this clinical setting

ANSWER: D

Rationale:

Option D is correct: thiazide diuretics lose meaningful natriuretic efficacy as eGFR falls, with significantly reduced efficacy at approximately eGFR <30 mL/min/1.73m²; at eGFR 34 — at the margin of this threshold — and with significant pitting edema indicating volume overload, a loop diuretic (furosemide, torsemide, or bumetanide) is the preferred choice because it acts on the Na-K-2Cl cotransporter in the thick ascending limb and retains efficacy throughout the CKD spectrum.

Option A: Option A is incorrect — thiazide efficacy is significantly impaired near the patient's eGFR; loop diuretics are preferred for volume overload at this level of renal function.
Option B: Option B is incorrect — while spironolactone has renoprotective benefit in CKD with diabetes (FIDELIO-DKD trial — finerenone in CKD with type 2 diabetes — demonstrated cardiorenal benefit), the primary clinical need here is volume reduction for significant edema, which is best addressed by a loop diuretic; hyperkalemia risk with spironolactone in CKD stage 3b on an ACE inhibitor is also a concern.
Option C: Option C is incorrect — diuresis for volume overload is clinically indicated and safe with appropriate monitoring; the concern about AKI from overly aggressive diuresis is managed by careful titration, not avoidance.
Option E: Option E is incorrect — amiloride blocks ENaC and is a potassium-sparing diuretic; in a patient on an ACE inhibitor with CKD stage 3b, adding amiloride creates high risk of life-threatening hyperkalemia through complementary potassium retention mechanisms.

8. A 56-year-old man with hypertension is found to have a serum sodium of 122 mEq/L and confusion 6 weeks after starting hydrochlorothiazide 25 mg daily. His baseline sodium before the thiazide was 138 mEq/L. Which of the following most accurately identifies the mechanism of thiazide-induced hyponatremia and the patient characteristics that should have predicted high risk?

A) Thiazide-induced hyponatremia occurs through direct inhibition of the Na-K-ATPase pump in collecting duct principal cells, producing obligatory sodium loss in all patients; the severity is dose-dependent and unpredictable without prior testing
B) Thiazide-induced hyponatremia occurs only in patients with pre-existing renal concentrating defects; a normal baseline kidney function test at thiazide initiation would have excluded this patient from risk
C) Thiazide-induced hyponatremia is caused by massive urinary sodium loss from natriuresis exceeding dietary intake; it is entirely predictable from baseline dietary sodium consumption and is prevented by increasing dietary sodium intake to compensate for urinary losses
D) The hyponatremia reflects thiazide-induced SIADH (syndrome of inappropriate antidiuretic hormone secretion) caused by direct stimulation of hypothalamic ADH release through a central pharmacological effect of the drug independent of volume status
E) Thiazide-induced hyponatremia results from free water retention — thiazide blockade of the NCC (Na-Cl cotransporter) in the distal convoluted tubule impairs urinary dilution in that segment; when combined with non-osmotic ADH release stimulated by volume contraction, the collecting duct reabsorbs free water that the diluting segment can no longer excrete; the highest-risk patients share a consistent profile: female sex, older age, low body weight, and baseline low-normal sodium — recognizing this profile should prompt closer monitoring, a lower starting dose, or selection of an alternative antihypertensive

ANSWER: E

Rationale:

Option E is correct: thiazides block NCC in the distal convoluted tubule, impairing the diluting segment's ability to generate dilute urine; when volume contraction from natriuresis stimulates non-osmotic ADH release, the collecting duct reabsorbs free water against a background of impaired diluting capacity — the result is dilutional hyponatremia; the highest-risk profile is female sex (estrogen may potentiate ADH sensitivity), older age (reduced total body water means the same free water retention produces a larger sodium drop), low body weight, and baseline low-normal sodium.

Option A: Option A is incorrect — thiazides do not inhibit Na-K-ATPase; they block NCC in the distal convoluted tubule; the hyponatremia mechanism is water retention, not sodium pump inhibition.
Option C: Option C is incorrect — the hyponatremia is dilutional (excess free water retention), not a pure sodium deficit from natriuresis exceeding intake; increasing dietary sodium does not correct the underlying impaired diluting mechanism.
Option D: Option D is incorrect — thiazides do not directly stimulate hypothalamic ADH release through a central pharmacological effect; the ADH stimulation is secondary to volume contraction sensed by baroreceptors.
Option B: Option B is incorrect — normal baseline renal function does not exclude the risk; thiazide-induced hyponatremia occurs in patients with normal renal function through the mechanism described and is determined by the risk factors listed, not prior renal concentrating capacity.

9. A 48-year-old woman with hypertension and primary aldosteronism (confirmed by ARR and positive saline infusion test) has bilateral adrenal hyperplasia on CT confirmed by AVS (adrenal vein sampling) showing bilateral aldosterone excess. She declines surgery and agrees to medical management. Which of the following most accurately describes the long-term pharmacological approach and its specific monitoring requirements?

A) Spironolactone or eplerenone is the etiologic treatment for bilateral adrenal hyperplasia — mineralocorticoid receptor antagonism directly addresses the autonomous aldosterone secretion driving her hypertension and hypokalemia; spironolactone is the more potent agent but carries anti-androgenic side effects (gynecomastia, menstrual irregularity) that may lead to preference for eplerenone in some patients; potassium, creatinine, and BP must be monitored closely, particularly when combined with ACE inhibitors or ARBs
B) Bilateral adrenalectomy is the only effective treatment for bilateral adrenal hyperplasia; medical therapy never achieves adequate BP or potassium control and should not be offered as a long-term option
C) Thiazide diuretics are the preferred agent for bilateral adrenal hyperplasia because they correct the volume expansion by promoting natriuresis; spironolactone should be avoided because it worsens the hypokalemia through potassium wasting at the level of the collecting duct
D) Fludrocortisone should be added to her antihypertensive regimen because bilateral adrenal hyperplasia causes relative mineralocorticoid deficiency that requires replacement therapy
E) ACE inhibitors alone are sufficient to treat primary aldosteronism from bilateral adrenal hyperplasia because RAAS blockade at the level of Ang II production eliminates the downstream signal for aldosterone secretion from the hyperplastic adrenal glands

ANSWER: A

Rationale:

Option A is correct: mineralocorticoid receptor antagonists — spironolactone (non-selective, more potent, anti-androgenic side effects) or eplerenone (selective, fewer off-target effects, preferred in men with gynecomastia or women with menstrual irregularity) — are the etiologic medical treatment for bilateral adrenal hyperplasia, directly blocking the aldosterone receptor that drives sodium retention, potassium wasting, and hypertension; close monitoring of potassium and renal function is required, especially if combined with RAAS inhibitors.

Option B: Option B is incorrect — bilateral adrenalectomy is not indicated for bilateral adrenal hyperplasia; surgery would cause Addison's disease requiring lifelong corticosteroid replacement and is not the standard approach; medical therapy with MR antagonists is effective and is the recommended long-term management.
Option C: Option C is incorrect — thiazides worsen hypokalemia (by stimulating collecting duct potassium secretion through volume depletion and aldosterone activation) and do not address the autonomous aldosterone excess; spironolactone specifically corrects the hypokalemia by blocking the mineralocorticoid receptor that drives potassium wasting.
Option D: Option D is incorrect — bilateral adrenal hyperplasia causes mineralocorticoid excess, not deficiency; fludrocortisone is a synthetic mineralocorticoid used for adrenal insufficiency and would profoundly worsen the hypertension and hypokalemia.
Option E: Option E is incorrect — bilateral adrenal hyperplasia involves autonomous aldosterone secretion that is independent of Ang II stimulation; ACE inhibitors reduce Ang II but cannot adequately suppress autonomous adrenal aldosterone production.

10. A 73-year-old man with hypertension and moderate aortic stenosis (valve area 1.4 cm², mean gradient 24 mmHg) has BP of 172/68 mmHg (pulse pressure 104 mmHg) and no symptoms of heart failure or syncope. His physician wants to lower his BP. Which of the following most accurately describes the pharmacological challenge specific to his aortic stenosis and the appropriate approach?

A) Aortic stenosis creates no specific pharmacological constraint for antihypertensive therapy; any standard agent can be used without modification
B) All antihypertensives are absolutely contraindicated in any degree of aortic stenosis because the fixed outflow obstruction means any reduction in preload or afterload will precipitate cardiac output collapse
C) Antihypertensive therapy in moderate aortic stenosis requires caution — the hypertrophied, pressure-overloaded LV (left ventricle) is stiff and preload-dependent; agents that abruptly reduce preload (aggressive diuresis, nitrates) or cause rapid large falls in systemic vascular resistance can precipitate a critical fall in cardiac output; however, untreated hypertension worsens the hemodynamic burden by further increasing afterload; careful gradual BP lowering with agents titrated slowly and avoidance of large preload-reducing agents is appropriate; ACE inhibitors have been studied in moderate AS and have shown hemodynamic benefit without harm
D) Beta-blockers are the only safe antihypertensive in aortic stenosis because their negative chronotropy prolongs diastolic filling time, which compensates for the fixed outflow obstruction and maintains cardiac output during any degree of BP reduction
E) Aggressive immediate BP lowering to below 120/80 mmHg is particularly important in aortic stenosis because hypertension in combination with valvular obstruction accelerates LV failure and the benefit of immediate normalization outweighs the hemodynamic risk

ANSWER: C

Rationale:

Option C is correct: moderate aortic stenosis creates specific hemodynamic constraints — the hypertrophied, preload-dependent LV requires adequate filling pressure to generate enough force to eject across the stenotic valve; agents that abruptly reduce preload or cause rapid falls in systemic vascular resistance can precipitate a sudden drop in cardiac output; however, untreated hypertension worsens afterload and accelerates LV hypertrophy; careful gradual BP lowering with close monitoring and avoidance of aggressive preload reduction is the correct approach, not abandonment of treatment.

Option A: Option A is incorrect — aortic stenosis creates specific hemodynamic constraints that must be considered in antihypertensive selection and titration.
Option B: Option B is incorrect — antihypertensives are not absolutely contraindicated in any degree of aortic stenosis; the degree of severity matters (severe symptomatic AS warrants much greater caution than moderate AS), and careful gradual lowering is safe and beneficial in moderate disease.
Option D: Option D is incorrect — beta-blockers are not the only safe antihypertensive in AS; while they do prolong diastolic filling time, they do not uniquely "compensate" for the fixed obstruction in a way that makes them the sole acceptable class.
Option E: Option E is incorrect — aggressive immediate normalization carries specific hemodynamic risk in aortic stenosis from the sudden afterload reduction in a preload-dependent LV; the approach must be gradual and carefully monitored.

11. A 55-year-old man with hypertension undergoes routine ABPM as part of a clinical trial. His report shows: office BP 136/84 mmHg (normal by ACC/AHA criteria); 24-hour mean 132/82 mmHg (above the ≥130/80 mmHg threshold); daytime mean 138/86 mmHg (above the ≥135/85 mmHg threshold); nighttime mean 124/78 mmHg (above the ≥120/70 mmHg nighttime threshold); nighttime dip 10.2%. His physician reviews the result and tells him he is normotensive based on the normal office BP. Which of the following most accurately identifies the error in this interpretation and its clinical consequence?

A) The physician's interpretation is correct — office BP is the gold standard for hypertension diagnosis and ABPM values are used only to monitor treatment, not to diagnose hypertension; the normal office reading definitively excludes hypertension
B) The physician has missed sustained hypertension — all three ABPM parameters (24-hour mean, daytime mean, and nighttime mean) exceed their respective diagnostic thresholds, confirming true sustained hypertension that is being underestimated by office measurement due to white coat effect in reverse; this patient requires antihypertensive therapy
C) The ABPM result confirms white coat hypertension — the office reading is elevated above the ABPM daytime mean, indicating that office measurement is artificially inflating the reading; the ABPM values are therefore unreliable and should be repeated
D) The ABPM report confirms masked hypertension — office BP is within the normal range (136/84 mmHg is below the ≥140/90 mmHg office threshold) but all out-of-office ABPM values exceed their diagnostic thresholds; masked hypertension carries cardiovascular risk equivalent to sustained hypertension and the physician's reassurance based on office BP alone is an error that leaves a clinically significant BP burden unaddressed and untreated
E) The nighttime dip of 10.2% is within the normal range (≥10%) so the ABPM result is clinically reassuring overall; the mildly elevated 24-hour and daytime means are within measurement noise and do not require treatment

ANSWER: D

Rationale:

Option D is correct: this patient has masked hypertension — office BP is 136/84 mmHg (below the office diagnostic threshold of ≥140/90 mmHg) but all ABPM parameters exceed their diagnostic thresholds (24-hour mean 132/82 mmHg ≥ 130/80 mmHg, daytime 138/86 mmHg ≥ 135/85 mmHg, nighttime 124/78 mmHg ≥ 120/70 mmHg); masked hypertension carries cardiovascular risk equivalent to sustained hypertension; the physician's reassurance based on normal office BP alone is an error that leaves clinically significant hypertension unaddressed.

Option A: Option A is incorrect — office BP is not the gold standard for diagnosing hypertension; ABPM is the gold standard and specifically identifies masked hypertension that office measurement misses.
Option B: Option B is incorrect — this is not sustained hypertension diagnosed by office measurement; the office reading is below threshold; this is specifically masked hypertension where out-of-office values are elevated with normal office values.
Option C: Option C is incorrect — white coat hypertension is the opposite pattern (elevated office BP with normal out-of-office values); this patient has normal office BP with elevated out-of-office values, which is masked hypertension.
Option E: Option E is incorrect — while the nighttime dip is reassuringly normal, all three ABPM diagnostic thresholds are exceeded; dismissing the elevated 24-hour and daytime means as measurement noise when both exceed their specific diagnostic thresholds is clinically incorrect.